Dachaigh › Cairtean uaine › DNAnexus, Inc.
DNAnexus, Inc.: sponsorachadh cairt uaine (PERM)
Chuir DNAnexus, Inc. 4 iarrtasan dearbhaidh obrach PERM a chaidh a dhearbhadh ann am bliadhnaichean ionmhais 2024–2026; dearbhte: 4. Tuarastal meadhanach tairgte $152,500; ùine mheadhanach bhon chur-a-steach chun dearbhadh: 477 làithean.
Iarrtasan PERM4
Dearbhte4
Tuarastal meadhanach a chaidh a thabhann$152,500
Làithean meadhanach gu dearbhadh477
Mar-thà ag obair don neach-fastaidh100%
Luchd-obrach (mar a chaidh a chur a-steach)140
Ann an gnìomhachas bho2009
Seòladh an neach-fhastaidhMountain View, CA
Tuarastalan H-1B aig DNAnexus, Inc. →
Tiotalan dreuchd
| Tiotal dreuchd | Iarrtasan PERM | Tuarastal meadhanach |
|---|---|---|
| Software Engineer | 1 | $184,662 |
| Principal Bioinformatics Scientist | 1 | $180,000 |
| Marketing Operations Analyst | 1 | $120,162 |
| Sr. Bioinformatics Scientist | 1 | $125,000 |
Làraich obrach
Gnìomhan
- Software Developers1
- Molecular and Cellular Biologists1
- Market Research Analysts and Marketing Specialists1
Co-dhùnaidhean as ùire
| Tiotal dreuchd | Tuarastal bunasach | Àite | Air a chur a-steach | Air a cho-dhùnadh | Inbhe | Làithean |
|---|---|---|---|---|---|---|
| Marketing Operations Analyst | $120,162–$130,162 | Mountain View, CA | 1 Iuch 2024 | 20 Samh 2025 | Dearbhte, a’ dol seachad | 507 |
| Software Engineer | $184,662–$194,662 | Mountain View, CA | 8 Màrt 2024 | 2 Iuch 2025 | Dearbhte | 481 |
| Principal Bioinformatics Scientist | $180,000–$190,000 | Mountain View, CA | 29 Sult 2023 | 14 Faoi 2025 | Dearbhte, a’ dol seachad | 473 |
| Sr. Bioinformatics Scientist | $125,000–$135,000 | Mountain View, CA | 21 Iuch 2023 | 25 Sult 2024 | Dearbhte | 432 |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications. PERM certification is one step toward a green card; USCIS decides the petition. Not legal advice. Source: U.S. Department of Labor, OFLC PERM Disclosure Data, fiscal years 2024–2026 (latest decision 30 Ògmh 2026).